ACTIVE

AgomAb Therapeutics

Financial year 2025 · Closed on 31/12/2025

Net result-9,6 M €+17,9 %over 1 year

Equity244,1 M €-3,8 %over 1 year

Workforce52,0 ETP+27,1 %over 1 year

Identity

Source · BCE/KBO

AgomAb Therapeutics is a Public limited company incorporated in 2017. Its main activity is: Technical testing and analysis. Its registered office is in Antwerpen. It employs on average 52,0 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0674.527.310
Incorporation: 13/04/2017
Legal form: Public limited company
Registered office: Posthoflei 1 box 6
2600 Antwerpen · FlandreSee on map
Contributed capital: 299 705 388,00 €
Latest accounts: 31/12/2025
Average workforce: 52,0 ETP

Activities (NACE)

71209Technical testing and analysis· main 71209Technical testing and analysis 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 72101Research and experimental development on natural sciences and engineering 72109Research and experimental development on natural sciences and engineering+2

Joint committees (1)

20700

Signals

Solid equityLow riskGood liquidityPositive cashflowHealthy social debts

Financials

Source · NBB, 9 filings

Trend over 8 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	–		4 M €	+168%	1,5 M €	+48.7%	993,2 k €	+119%	-5,3 M €
EBITDA	-2,3 M €	+48.4%	-4,5 M €	-44.5%	-3,1 M €	-77.7%	-1,7 M €	+73.1%	-6,5 M €
Operating result	-14,2 M €	+3.7%	-14,7 M €	-51.0%	-9,8 M €	+0.6%	-9,8 M €	-51.5%	-6,5 M €
Net result	-9,6 M €	+17.9%	-11,7 M €	-38.8%	-8,4 M €	+10.2%	-9,4 M €	-44.9%	-6,5 M €
Balance sheet
Equity	244,1 M €	-3.8%	253,7 M €	+38.4%	183,3 M €	+89.2%	96,9 M €	+42.7%	67,9 M €
Total assets	251,3 M €	-2.8%	258,7 M €	+37.1%	188,7 M €	+86.3%	101,3 M €	+37.2%	73,8 M €
Cash	73 M €	+195%	24,8 M €	-79.7%	121,9 M €	+354%	26,9 M €	-49.0%	52,7 M €
Debts	5,7 M €	+39.9%	4,1 M €	-2.4%	4,2 M €	+85.7%	2,3 M €	-60.0%	5,6 M €
Other
Workforce	52,0 ETP	+27.1%	40,9 ETP	+111%	19,4 ETP	+92.1%	10,1 ETP	+166%	3,8 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

7 active · 11 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Colin Bond	Director15/11/2024 → 28/05/2030
David Epstein	Director08/07/2024 → 28/05/2030
Angelika Martha Jahreis	Director10/10/2023 → 09/10/2029
Felice Verduyn - van Weegen	Director10/10/2023 → 24/04/2029
Xiaoming Fang	Director10/10/2023 → 24/04/2029
Tim Knotnerus	Managing director05/03/2021 → 04/03/2027Director22/02/2018 → 2024 accountsended
Ohad Hammer	Director14/03/2019 → 26/05/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Felice Isabel van Weegen	Director10/10/2023 → 2023 accounts
Michael Lee	Director05/03/2021 → 2023 accounts
Johannes Zanzinger	Director27/06/2019 → 05/03/2021

Other companies at this address

Posthoflei 1 2600 Antwerpen

Company	CBE no.
Science at Work Staffing België● Active	0748.569.982
THE HOUSE OF DEVELOPMENT● Active	0547.666.948

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	23/06/2026	03/06/2025	27/06/2024	03/07/2023	29/06/2022	24/05/2021
General meeting	26/05/2026	30/05/2025	28/05/2024	30/06/2023	15/06/2022	27/04/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 9 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	26/05/2026	23/06/2026	Dutch	PDF
Abridged model	31/12/2024	30/05/2025	03/06/2025	Dutch	PDF
Abridged model	31/12/2023	28/05/2024	27/06/2024	Dutch	PDF
Abridged model	31/12/2022	30/06/2023	03/07/2023	Dutch	PDF
Abridged model	31/12/2021	15/06/2022	29/06/2022	Dutch	PDF
Abridged model	31/12/2020	27/04/2021	24/05/2021	Dutch	PDF
Abridged model	31/12/2019	28/04/2020	18/05/2020	Dutch	PDF
Micro model	31/12/2018	26/06/2019	11/07/2019	Dutch	PDF
Micro model	31/12/2017	24/04/2018	13/05/2018	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

7 active · 11 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Colin Bond	Director15/11/2024 → 28/05/2030
David Epstein	Director08/07/2024 → 28/05/2030
Angelika Martha Jahreis	Director10/10/2023 → 09/10/2029
Felice Verduyn - van Weegen	Director10/10/2023 → 24/04/2029
Xiaoming Fang	Director10/10/2023 → 24/04/2029
Tim Knotnerus	Managing director05/03/2021 → 04/03/2027Director22/02/2018 → 2024 accountsended
Ohad Hammer	Director14/03/2019 → 26/05/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Felice Isabel van Weegen	Director10/10/2023 → 2023 accounts
Michael Lee	Director05/03/2021 → 2023 accounts
Johannes Zanzinger	Director27/06/2019 → 05/03/2021

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Capital / shares26/10/2026
KAPITAAL, AANDELEN
PDF
Mandates12/10/2026
ONTSLAGEN, BENOEMINGEN
PDF
Mandates19/06/2026
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares17/04/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Capital / shares08/04/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Mandates11/03/2026
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares26/02/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Mandates17/06/2025
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings8 filings

Mandates

Colin Bond

David Epstein

Angelika Martha Jahreis

Felice Verduyn - van Weegen

Xiaoming Fang

Tim Knotnerus

Ohad Hammer

Felice Isabel van Weegen

Michael Lee

Johannes Zanzinger

Claire Poulard

John Haurum

Show the 6 other mandates

20172018201920202021202220232024202520262027202820292030

AgomAb Therapeutics

Posthoflei 1 bte 6, 2600 Berchem (Antwerp)Franklin Rooseveltlaan 348, 9000 Gent

Director

Managing directorDirector

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Posthoflei 1 bte 6, 2600 Berchem (Antwerp)Current	accounts 2023 → 2025	Accounts 2025 · 2026-00200444
Franklin Rooseveltlaan 348, 9000 Gent	accounts 2021 → 2022	Accounts 2022 · 2023-00212996

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
AgomAb TherapeuticsCurrent	accounts 2017 → 2025	Accounts 2025 · 2026-00200444

Events

26/05/2026
reconductionOhad Hammer · bestuurder
26/05/2026
reconductionTim Knotnerus · bestuurder
12/03/2026
augmentation_capital
04/03/2026
augmentation_capital
16/01/2026
unknownAngelika Martha Jahreis · Onafhankelijk Bestuurder
16/01/2026
unknownColin Bond · Onafhankelijk Bestuurder
16/01/2026
unknownDavid Epstein · Voorzitter Bestuurder en Onafhankelijk Bestuurder
16/01/2026
unknownFelice Isabel Verduyn - Van Weegen · Klasse C Investeerder Bestuurder
16/01/2026
unknownOhad Hammer · Klasse A Investeerder Bestuurder
16/01/2026
unknownTim Knotnerus · CEO Bestuurder
15/01/2026
augmentation_capital
2025
Annual accounts 2025-9,6 M €↑
30/05/2025
reconductionOhad Hammer · Klasse A Investeerder Bestuurder
2024
Annual accounts 2024-11,7 M €↓
04/11/2024
augmentation_capital
08/07/2024
nominationDavid Epstein · Voorzitter Bestuurder
28/05/2024
reconductionPwC Bedrijfsrevisoren BV · commissaris
28/05/2024
reconductionOhad Hammer · Klasse B Investeerder Bestuurder
28/05/2024
reconductionJohn Haurum · Voorzitter Bestuurder en Onafhankelijk Bestuurder
2023
Annual accounts 2023-8,4 M €↑
2022
Annual accounts 2022-9,4 M €↓
2021
Annual accounts 2021-6,5 M €↓
2019
Annual accounts 2019-3,1 M €↓
2018
Annual accounts 2018-393,3 k €↓
2017
Annual accounts 2017-116,7 k €
13/04/2017
IncorporationPublic limited company

AgomAb Therapeutics

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events